Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Authors:
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , 292-300
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 15 references indexed in Scilit:
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyThe Lancet, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDYJournal of Hepatology, 2014
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infectionJournal of Hepatology, 2014
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resourceHepatology, 2013
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelLiver International, 2011
- A systematic review of hepatitis C virus epidemiology in Asia, Australia and EgyptLiver International, 2011
- The global health burden of hepatitis C virus infectionLiver International, 2011
- Estimation of Survival Distributions of Treatment Policies in Two‐Stage Randomization Designs in Clinical TrialsBiometrics, 2002